Theravance Biopharma, Inc.
TBPH
$8.60
-$0.035-0.41%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 88.35M | 91.36M | 96.08M | 99.98M | 102.43M |
| Total Receivables | 68.44M | 16.85M | 14.30M | 14.66M | 17.47M |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 4.28M | 8.27M | 8.93M | 9.66M | 13.64M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 161.07M | 116.48M | 119.31M | 124.29M | 133.54M |
|
|
|||||
| Total Current Assets | 161.07M | 116.48M | 119.31M | 124.29M | 133.54M |
| Net Property, Plant & Equipment | 35.77M | 37.12M | 39.96M | 44.08M | 45.36M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 157.32M | 202.50M | 202.77M | 202.93M | 203.10M |
| Total Assets | 354.16M | 356.11M | 362.03M | 371.31M | 382.00M |
|
|
|||||
| Total Accounts Payable | 2.24M | 1.45M | 1.67M | 1.69M | 1.52M |
| Total Accrued Expenses | 13.28M | 11.30M | 10.56M | 9.42M | 12.83M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 10.71M | 4.20M | 4.22M | 4.06M | 3.92M |
| Total Finance Division Other Current Liabilities | 5.85M | 6.49M | 6.49M | 6.49M | 6.49M |
| Total Other Current Liabilities | 5.85M | 6.49M | 6.49M | 6.49M | 6.49M |
| Total Current Liabilities | 32.09M | 23.44M | 22.95M | 21.66M | 24.77M |
|
|
|||||
| Total Current Liabilities | 32.09M | 23.44M | 22.95M | 21.66M | 24.77M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 39.11M | 40.79M | 42.44M | 43.84M | 45.24M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 107.42M | 106.23M | 102.95M | 100.94M | 99.00M |
| Total Liabilities | 178.62M | 170.45M | 168.34M | 166.44M | 169.00M |
|
|
|||||
| Common Stock & APIC | 1.14B | 1.14B | 1.13B | 1.13B | 1.12B |
| Retained Earnings | -965.52M | -950.00M | -937.30M | -920.77M | -909.10M |
| Treasury Stock & Other | 7.00K | 50.00K | -22.00K | -41.00K | -65.00K |
| Total Common Equity | 175.55M | 185.65M | 193.69M | 204.87M | 213.00M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 175.55M | 185.65M | 193.69M | 204.87M | 213.00M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 175.55M | 185.65M | 193.69M | 204.87M | 213.00M |
|
|
|||||